Cargando…
Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum
The emergence of resistance to first-line antimalarials, including artemisinin, the last effective malaria therapy in some regions, stresses the urgent need to develop new effective treatments against this disease. The identification and validation of metabolic pathways that could be targeted for dr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841962/ https://www.ncbi.nlm.nih.gov/pubmed/35222844 http://dx.doi.org/10.1016/j.csbj.2022.01.029 |
_version_ | 1784650955553243136 |
---|---|
author | Fenollar, Àngel Ros-Lucas, Albert Pía Alberione, María Martínez-Peinado, Nieves Ramírez, Miriam Ángel Rosales-Motos, Miguel Y. Lee, Ling Alonso-Padilla, Julio Izquierdo, Luis |
author_facet | Fenollar, Àngel Ros-Lucas, Albert Pía Alberione, María Martínez-Peinado, Nieves Ramírez, Miriam Ángel Rosales-Motos, Miguel Y. Lee, Ling Alonso-Padilla, Julio Izquierdo, Luis |
author_sort | Fenollar, Àngel |
collection | PubMed |
description | The emergence of resistance to first-line antimalarials, including artemisinin, the last effective malaria therapy in some regions, stresses the urgent need to develop new effective treatments against this disease. The identification and validation of metabolic pathways that could be targeted for drug development may strongly contribute to accelerate this process. In this study, we use fully characterized specific inhibitors targeting glycan biosynthetic pathways as research tools to analyze their effects on the growth of the malaria parasite Plasmodium falciparum and to validate these metabolic routes as feasible chemotherapeutic targets. Through docking simulations using models predicted by AlphaFold, we also shed new light into the modes of action of some of these inhibitors. Molecules inhibiting N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (GlcNAc-PI de-N-acetylase, PIGL/GPI12) or the inositol acyltransferase (GWT1), central for glycosylphosphatidylinositol (GPI) biosynthesis, halt the growth of intraerythrocytic asexual parasites during the trophozoite stages of the intraerythrocytic developmental cycle (IDC). Remarkably, the nucleoside antibiotic tunicamycin, which targets UDP-N-acetylglucosamine:dolichyl-phosphate N-acetylglucosaminephosphotransferase (ALG7) and N-glycosylation in other organisms, induces a delayed-death effect and inhibits parasite growth during the second IDC after treatment. Our data indicate that tunicamycin induces a specific inhibitory effect, hinting to a more substantial role of the N-glycosylation pathway in P. falciparum intraerythrocytic asexual stages than previously thought. To sum up, our results place GPI biosynthesis and N-glycosylation pathways as metabolic routes with potential to yield much-needed therapeutic targets against the parasite. |
format | Online Article Text |
id | pubmed-8841962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Research Network of Computational and Structural Biotechnology |
record_format | MEDLINE/PubMed |
spelling | pubmed-88419622022-02-25 Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum Fenollar, Àngel Ros-Lucas, Albert Pía Alberione, María Martínez-Peinado, Nieves Ramírez, Miriam Ángel Rosales-Motos, Miguel Y. Lee, Ling Alonso-Padilla, Julio Izquierdo, Luis Comput Struct Biotechnol J Research Article The emergence of resistance to first-line antimalarials, including artemisinin, the last effective malaria therapy in some regions, stresses the urgent need to develop new effective treatments against this disease. The identification and validation of metabolic pathways that could be targeted for drug development may strongly contribute to accelerate this process. In this study, we use fully characterized specific inhibitors targeting glycan biosynthetic pathways as research tools to analyze their effects on the growth of the malaria parasite Plasmodium falciparum and to validate these metabolic routes as feasible chemotherapeutic targets. Through docking simulations using models predicted by AlphaFold, we also shed new light into the modes of action of some of these inhibitors. Molecules inhibiting N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (GlcNAc-PI de-N-acetylase, PIGL/GPI12) or the inositol acyltransferase (GWT1), central for glycosylphosphatidylinositol (GPI) biosynthesis, halt the growth of intraerythrocytic asexual parasites during the trophozoite stages of the intraerythrocytic developmental cycle (IDC). Remarkably, the nucleoside antibiotic tunicamycin, which targets UDP-N-acetylglucosamine:dolichyl-phosphate N-acetylglucosaminephosphotransferase (ALG7) and N-glycosylation in other organisms, induces a delayed-death effect and inhibits parasite growth during the second IDC after treatment. Our data indicate that tunicamycin induces a specific inhibitory effect, hinting to a more substantial role of the N-glycosylation pathway in P. falciparum intraerythrocytic asexual stages than previously thought. To sum up, our results place GPI biosynthesis and N-glycosylation pathways as metabolic routes with potential to yield much-needed therapeutic targets against the parasite. Research Network of Computational and Structural Biotechnology 2022-02-02 /pmc/articles/PMC8841962/ /pubmed/35222844 http://dx.doi.org/10.1016/j.csbj.2022.01.029 Text en © 2022 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Fenollar, Àngel Ros-Lucas, Albert Pía Alberione, María Martínez-Peinado, Nieves Ramírez, Miriam Ángel Rosales-Motos, Miguel Y. Lee, Ling Alonso-Padilla, Julio Izquierdo, Luis Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum |
title | Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum |
title_full | Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum |
title_fullStr | Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum |
title_full_unstemmed | Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum |
title_short | Compounds targeting GPI biosynthesis or N-glycosylation are active against Plasmodium falciparum |
title_sort | compounds targeting gpi biosynthesis or n-glycosylation are active against plasmodium falciparum |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841962/ https://www.ncbi.nlm.nih.gov/pubmed/35222844 http://dx.doi.org/10.1016/j.csbj.2022.01.029 |
work_keys_str_mv | AT fenollarangel compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT roslucasalbert compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT piaalberionemaria compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT martinezpeinadonieves compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT ramirezmiriam compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT angelrosalesmotosmiguel compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT yleeling compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT alonsopadillajulio compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum AT izquierdoluis compoundstargetinggpibiosynthesisornglycosylationareactiveagainstplasmodiumfalciparum |